Liver study tests how MCI-186 behaves in severe impairment

NCT ID NCT03664544

Completed Knowledge-focused Sponsor: Shionogi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This completed Phase 1 study looked at how the drug MCI-186 (Edaravone) is processed in the body of people with severe liver impairment compared to healthy individuals. Twelve participants received a single intravenous dose. The goal was to measure drug levels and safety, not to treat any condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MCI-186 (Edaravone, Radicava, Radicut)
What this could lead to: If successful, this study could help doctors understand how to safely dose MCI-186 in patients with severe liver problems.
What could go wrong: This is a very small, early-phase study (12 people) focused on drug processing, not on treating any disease. Results may not apply to broader populations or predict real-world safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY SEVERE HEPATIC IMPAIRMENT

Contacts and locations

Locations

Investigational Centre

Prague, Czechia
Investigational Centre

Miskolc, Hungary
Investigational Centre

Bratislava, Slovakia

More trials for these conditions

Other studies related to the condition(s) this trial covers.